Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01ZXW
|
|||
| Former ID |
DCL000149
|
|||
| Drug Name |
Lintitript
|
|||
| Synonyms |
SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66] | Discontinued in Phase 2 | [1], [2] | |
| Pancreatic cancer [ICD-11: 2C10] | Discontinued in Phase 2 | [1], [2] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Sanofi-aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H14ClN3O3S
|
|||
| Canonical SMILES |
C1=CC=C2C(=C1)C=C(N2CC(=O)O)C(=O)NC3=NC(=CS3)C4=CC=CC=C4Cl
|
|||
| InChI |
1S/C20H14ClN3O3S/c21-14-7-3-2-6-13(14)15-11-28-20(22-15)23-19(27)17-9-12-5-1-4-8-16(12)24(17)10-18(25)26/h1-9,11H,10H2,(H,25,26)(H,22,23,27)
|
|||
| InChIKey |
ILNRQFBVVQUOLP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 136381-85-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7980659, 10239927, 14806438, 29302530, 47583729, 48105187, 50064374, 50112865, 52854802, 57339937, 85209316, 85787643, 103555631, 104414961, 123121570, 124893352, 128185397, 134338829, 135079374, 135650524, 135697565, 136350276, 142014418, 144206134, 162023385, 162312829, 163304545, 170466345, 175426876, 175612460, 176223166, 179149861, 198988061, 204359779, 226414792, 241375812, 252156343, 252159988
|
|||
| ChEBI ID |
CHEBI:92624
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cholecystokinin receptor type A (CCKAR) | Target Info | Antagonist | [3], [4] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Insulin secretion | ||||
| Pancreatic secretion | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 890). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004912) | |||
| REF 3 | A cholecystokinin-1 receptor agonist (CCK-8) mediates increased permeability of brain barriers to leptin. Br J Pharmacol. 2008 Jul;154(5):1009-15. | |||
| REF 4 | A novel role for cholecystokinin: regulation of mesenteric vascular resistance. Regul Pept. 2004 Sep 15;121(1-3):145-53. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.